All In Biotech

Drug Trial Radar · NCT05208762

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

714

Planned (sponsor's estimate)

Start

Oct 25, 2022

Primary completion

Jan 5, 2028

Study completion Jan 4, 2029

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma of the Head and Neck
  • Esophageal Squamous Cell Carcinoma
  • Triple Negative Breast Neoplasms
  • Gastric Cancer
  • Endometrial Cancer
  • Pancreatic Adenocarcinoma
  • Hepatocellular Carcinoma

Interventions

  • PF-08046054Drug

    Given into the vein (IV; intravenously)

  • pembrolizumabDrug

    200 mg once every 3 weeks given into the vein (IV; intravenously)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Through approximately 90 days after last study treatment; up to 3 years
  2. Number of participants with laboratory abnormalitiesTime frame: Through approximately 90 days after last study treatment; up to 3 years
  3. Number of participants with dose-limiting toxicities (DLTs)Time frame: Through the first cycle of study treatment; approximately 1 month
  4. Number of participants with DLTs by dose levelTime frame: Through the first cycle of study treatment; approximately 1 month

Locations

62 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham, IDS Pharmacy

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of California, Davis Medical Center

    Sacramento, California · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Karmanos Cancer Institute

    Farmington Hills, Michigan · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • University of Texas Southwestern Medical Center - Simmons Cancer Center

    Dallas, Texas · Recruiting

  • UT Southwestern Medical Center - Redbird

    Dallas, Texas · Recruiting

  • Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital

    Dallas, Texas · Recruiting

  • University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital

    Dallas, Texas · Recruiting

  • University Of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • UT Southwestern - Simmons Cancer Center - Fort Worth

    Fort Worth, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services

    Houston, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • UT Southwestern - Simmons Cancer Center - Richardson/Plano

    Richardson, Texas · Recruiting

  • NEXT Virginia, LLC

    San Antonio, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

  • University Health Network, Princess Margaret Hospital

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Beijing Friendship hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Hôpital Saint André - CHU Bordeaux

    Bordeaux, France · Recruiting

  • Clinique Ambroise Pare

    Neuilly-sur-Seine, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • lnstitut Curie Pharmacy

    Paris, France · Recruiting

  • Gustave Roussy Institute - Service pharmacie

    Villejuif, France · Recruiting

  • Gustave Roussy Institute

    Villejuif, France · Recruiting

  • Charite Comprehensive Cancer Center

    Berlin, Germany · Recruiting

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.